Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Radiopharmaceutical CDMO Market to Accelerate Substantially at a CAGR of ~10% by 2034 | DelveInsight

globenewswire.com
TMO Thermo Fisher Scientific Inc. is listed as a key CDMO company in the radiopharmaceutical market. The article highlights the growth of this sector but offers no specific sentiment for Thermo Fisher. MRK Merck & Co. Inc. is listed as a key CDMO company in the radiopharmaceutical market. The article discusses industry growth but does not provide specific sentiment for Merck. DHR Danaher Corporation is named as a key CDMO company in the radiopharmaceutical market. The article highlights the market's growth potential but offers no specific sentiment for Danaher. LNT Lantheus is identified as a key radiopharmaceutical company. The article discusses the growth of the radiopharmaceutical market, which is relevant to Lantheus, but provides no specific sentiment. THC Cardinal Health is mentioned as a key radiopharmaceutical company. The article discusses the growth of the radiopharmaceutical market, which is relevant to Cardinal Health, but provides no specific sentiment. GEHC GE Healthcare is listed as a key radiopharmaceutical company. The article highlights the expanding radiopharmaceutical market but offers no specific sentiment for GE Healthcare. NVS Novartis is mentioned as a key radiopharmaceutical and radioligand therapy company. The article discusses market growth but provides no specific sentiment for Novartis. LLY Eli Lilly and Company is listed as a key company in the radioligand therapies market. The article discusses the growth of this sector but offers no specific sentiment for Eli Lilly. AZN AstraZeneca is mentioned as a key company in the radioligand therapies market. The article discusses the growth of this sector but offers no specific sentiment for AstraZeneca.

Global Radiopharmaceutical CDMO Market to Accelerate Substantially at a CAGR of ~10% by 2034 | DelveInsight New York, USA, July 29, 2026 (GLOBE NEWSWIRE) -- Global Radiopharmaceutical CDMO Market to Accelerate Substantially at a CAGR of ~10% by 2034 | DelveInsight

The radiopharmaceutical CDMO market is experiencing strong growth, driven by the expanding clinical and commercial pipeline of targeted radiotherapies and radiodiagnostics. Rising demand for specialized manufacturing capabilities, stringent regulatory requirements, and the need for reliable isotope handling are encouraging pharmaceutical and biotechnology companies to increasingly outsource development and production. Growing investments in isotope production infrastructure, GMP-compliant manufacturing facilities, and global supply chain networks are further supporting market expansion.

DelveInsight’s Radiopharmaceutical CDMO Market Insights report provides the current and forecast market analysis, individual leading radiopharmaceutical CDMO companies’ market shares, challenges, radiopharmaceutical CDMO market drivers, barriers, trends, and key radiopharmaceutical CDMO companies in the market.

Radiopharmaceutical CDMO Market Summary

To read more about the latest highlights related to the radiopharmaceutical CDMO market, get a snapshot of the key highlights @ https://www.delveinsight.com/report-store/radiopharmaceutical-cdmo-market

Key Factors Contributing to the Rise in Growth of the Radiopharmaceutical CDMO Market

Get a sneak peek at the radiopharmaceutical CDMO market dynamics @ Radiopharmaceutical CDMO Market Trends

Regional Radiopharmaceutical CDMO Market Insights

North America

Europe

Asia-Pacific

To know more about why North America is leading the market growth in the radiopharmaceutical CDMO market, get a snapshot of the Radiopharmaceutical CDMO Market Share

Recent Developmental Activities in the Radiopharmaceutical CDMO Market

What is the Radiopharmaceutical CDMO?

A radiopharmaceutical CDMO is a specialized service provider that supports the research, development, manufacturing, quality control, regulatory compliance, and commercial production of radiopharmaceuticals used for diagnostic imaging and targeted radionuclide therapy. These organizations possess the infrastructure, technical expertise, and regulatory capabilities required to safely handle radioactive isotopes, formulate radiolabeled compounds, and manufacture products in compliance with Good Manufacturing Practice (GMP) standards. Radiopharmaceutical CDMOs offer end-to-end services, including process development, analytical testing, radiolabeling, sterile fill-finish, packaging, logistics, and distribution, enabling pharmaceutical and biotechnology companies to accelerate product development while minimizing the need for substantial capital investment. With the growing adoption of precision medicine and theranostics in oncology and other therapeutic areas, radiopharmaceutical CDMOs have become essential partners in ensuring the reliable, scalable, and compliant production of these highly specialized therapies.

Radiopharmaceutical CDMO Market Assessment

Which MedTech key players in the radiopharmaceutical CDMO market are set to emerge as the trendsetter explore @ Radiopharmaceutical CDMO Market Analysis

Table of Contents

Interested in knowing the radiopharmaceutical CDMO market share by 2034? Click to get a snapshot of the Radiopharmaceutical CDMO Market Size

Related Reports

Contract Development Manufacturing Organization Market

Contract Development Manufacturing Organization Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key CDMO companies such as Catalent Inc., Thermo Fisher Scientific Inc., The Lubrizol Corporation, Recipharm (EQT), Cambrex Corporation, Merck & Co. Inc., AGC Biologics, Nerpharma S.r.l., Danaher Corporation, EMERGENT, Onyx Scientific Limited, Lonza, Siegfried Holding AG, CordenPharma International, FUJIFILM Diosynth Biotechnologies, Samsung Biologics, Delpharm, Revvity Inc., WuXi Biologics, Laboratoire Elaiapharm, and others.

Biologics Drug Substance Fill and Finish Manufacturing Market

Biologics Drug Substance Fill and Finish Manufacturing Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key biologics drug substance fill and finish manufacturing companies, including JOINN Biologics, Pharmaron, Symbiosis Pharmaceutical Services, AGC Biologics, INCOG BioPharma Services, CPC, Eurofins Scientific, and others.

Biologics Contract Manufacturing Market

Biologics Contract Manufacturing Market Insights, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key biologics contract manufacturing companies, including Boehringer Ingelheim, Catalent, Lonza, WuXi Biologics, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, AbbVie, AGC Biologics, and others.

Radiopharmaceuticals Market

Radiopharmaceuticals Market Insight, Competitive Landscape, and Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key radiopharmaceuticals companies, including Lantheus, Cardinal Health, GE Healthcare, Curium Pharma, Pharmalogic Holdings Corp., Novartis, Cambridge Isotope Laboratories, Inc., Sotera Health LLC, Bracco Imaging SpA, Jubilant Pharma Limited, NECSA Ltd., IBA Radiopharma Solutions, Bayer AG, Norgine, NorthStar Medical Radioisotopes, LLC, Eckert & Ziegler, Telix Pharmaceuticals Limited, ITM Isotope Technologies Munich SE, Mallinckrodt PLC, ROTOP Pharmaka GmbH, and others.

Radioligand Therapies Market

Radioligand Therapies Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key RLT companies, including Novartis, Curium Pharma, Lantheus, Eli Lilly and Company, Fusion Pharmaceuticals, AstraZeneca, Clarity Pharmaceuticals, Bayer, ITM Isotope Technologies, ARTBIO, Convergent Therapeutics, Perspective Therapeutics, PRECIRIX, Ariceum Therapeutic, Nuclidium, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.